Switch to
More onapp

How to use scorecard? Learn more

Gennex Laboratories Ltd

GENNEX
Health CarePharmaceuticals
SmallcapWith a market cap of ₹417 cr, stock is ranked 1,993
High RiskStock is 4.13x as volatile as Nifty
17.990.10 (+0.56%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹417 cr, stock is ranked 1,993
High RiskStock is 4.13x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
24.14
PB RatioPB Ratio
2.37
Dividend YieldDiv. Yield
Sector PESector PE
51.53
Sector PBSector PB
6.56
Sector Div YldSctr Div Yld
0.52%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Gennex Laboratories Limited is engaged in manufacturing of bulk drugs, intermediates and biotech products. Its product portfolio is spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal.

Financial TrendFinancial statements 

202120222023202460.1762.5969.5691.624.043.924.9313.17
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Company Update 
Announced OnNov 16, 2024

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Download

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Download

Result 
Announced OnNov 14, 2024

GENNEX LABORATORIES LTD. - 531739 - Financial Results For The Quarter And Half Year Ended September 30, 2024 | Download

GENNEX LABORATORIES LTD. - 531739 - Financial Results For The Quarter And Half Year Ended September 30, 2024 | Download

Board Meeting 
Announced OnNov 14, 2024

GENNEX LABORATORIES LTD. - 531739 - Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited - Scrip Code: 531739/GENNEX | Download

GENNEX LABORATORIES LTD. - 531739 - Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited - Scrip Code: 531739/GENNEX | Download

See all events